A Unified Hypothesis of Early- and Late-Onset Alzheimer’s Disease Pathogenesis
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Early-onset familial Alzheimer's disease (EOFAD) and late-onset sporadic AD (LOSAD) both follow a similar pathological and biochemical course that includes: neuron and synapse loss and dysfunction, microvascular damage, microgliosis, extracellular amyloid-β deposition, tau phosphorylation, formation of intracellular neurofibrillary tangles, endoreduplication and related cell cycle events in affected brain regions. Any mechanistic explanation of AD must accommodate these biochemical and neuropathological features for both forms of the disease. In this insight paper we provide a unifying hypothesis for EOFAD and LOSAD that proposes that the aberrant re-entry of terminally differentiated, post-mitotic neurons into the cell division cycle is a common pathway that explains both early and late-onset forms of AD. Cell cycle abnormalities appear very early in the disease process, prior to the appearance of plaques and tangles, and explain the biochemical (e.g. tau phosphorylation), neuropathological (e.g. neuron hypertrophy; polypoidy) and cognitive changes observed in EOFAD and LOSAD. Genetic mutations in AβPP, PSEN1, and PSEN2 that alter amyloid-β precursor protein and Notch processing drive reactivation of the cell cycle in EOFAD, while age-related reproductive endocrine dyscrasia that upregulates mitogenic TNF signaling and AβPP processing toward the amyloidogenic pathway drives reactivation of the cell cycle in LOSAD. In essence, AβPP and presenilin mutations initiate early, what endocrine dyscrasia initiates later: aberrant cell cycle re-entry of post-mitotic neurons leading to neurodegeneration and cognitive decline in AD. Inhibition of cell cycle re-entry in post-mitotic neurons may be a useful therapeutic strategy to prevent, slow or halt disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Oxidative Damage Is the Earliest Event in Alzheimer Disease
Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.759 · Cited by 1,885 · cited 1×
“Pyramidal neurons of the AD brain contain 3-fold elevated levels of cytoplasmic mitochondrial DNA and increased Cox-1 expression, indicative of de novo mitochondrion synthesis that would be expected during cell division to meet the energy demands of the newly created daughter cells [24].”
Self-citationBorchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C.-M., Kim, G., Seekins, S., Yager, D., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80230-5 · Cited by 1,478
Mitochondrial abnormalities in Alzheimer's disease
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., Johnson, A. B., Kress, Y., Vinters, H. V., Tabaton, M., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-09-03017.2001 · Cited by 1,367 · cited 1×
“Mitochondrial alterations—Changes suggestive of mitochondria replication have been reported in those neurons vulnerable to AD neuropathology [23].”
Self-citationCitron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-wood, K., Lee, M., Seubert, P., Davis, A., et al. (1997) · Nature Medicine · doi:10.1038/nm0197-67 · Cited by 1,271 · cited 1×
“The overexpression of EOFAD mutant A PP, which promotes A generation [64], has been shown to promote the aberrant re-entry of primary neurons into the cell cycle, as demonstrated by the initial induction of DNA synthesis and cell cycle marker expression, followed by apoptotic cell death [65].”
BackgroundApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050
Tau pathology in Alzheimer disease and other tauopathies
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., Khatoon, S., Li, B., Liu, F., Rahman, A., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.008 · Cited by 1,037 · cited 1×
“Therefore, it is interesting that hyperphosphorylation of the microtubule-associated protein tau, as detected in NFT, is one of the major pathological features of neuronal degeneration in AD [52], and indicates attempted division of pyramidal neurons in AD.”
Rocca, W. A., Bower, J. H., Maraganore, D. M., Ahlskog, J. E., Grossardt, B. R., de Andrade, M., & Melton, L. J. (2007) · Neurology · doi:10.1212/01.wnl.0000276984.19542.e6 · Cited by 827
Hippocampal Neurogenesis Regulates Forgetting During Adulthood and Infancy
Akers, K. G., Martinez-Canabal, A., Restivo, L., Yiu, A. P., De Cristofaro, A., Hsiang, H.-L. (., Wheeler, A. L., Guskjolen, A., Niibori, Y., Shoji, H., et al. (2014) · Science · doi:10.1126/science.1248903 · Cited by 761
Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies
Andersen, K., Launer, L. J., Dewey, M. E., Letenneur, L., Ott, A., Copeland, J. R. M., Dartigues, J.-F., Kragh–Sorensen, P., Baldereschi, M., Brayne, C., et al. (1999) · Neurology · doi:10.1212/wnl.53.9.1992 · Cited by 650
Ectopic Cell Cycle Proteins Predict the Sites of Neuronal Cell Death in Alzheimer’s Disease Brain
Busser, J., Geldmacher, D. S., & Herrup, K. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-08-02801.1998 · Cited by 543
Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer’s disease
Yang, Y., Mufson, E. J., & Herrup, K. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02557.2003 · Cited by 483 · cited 5×
“This genetic imbalance seems to persist for many months before the neurons die [22, 42] and this genomic replication without cytokinesis (endoreduplication) will have dramatic implications for the overexpression of neuronal proteins such as amyloid-β protein precursor (AβPP), as is the case with Down syndrome [45] and…”
InfluentialExpression of the cyclin-dependent kinase inhibitor p16 in Alzheimerʼs disease
Lars Rödel, T. A., Gärtner, U., & Holzer, M. (1996) · NeuroReport · doi:10.1097/00001756-199611250-00050 · Cited by 250
Iacono (2009) · doi:10.1212/wnl.0b013e3181b01077 · Cited by 203
Neuronal Hypertrophy in Asymptomatic Alzheimer Disease
Iacono, D., O'Brien, R., Resnick, S. M., Zonderman, A. B., Pletnikova, O., Rudow, G., An, Y., West, M. J., Crain, B., & Troncoso, J. C. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181772794 · Cited by 188
Neuropathologic Studies of the Baltimore Longitudinal Study of Aging (BLSA)
O'Brien, R. J., Resnick, S. M., Zonderman, A. B., Ferrucci, L., Crain, B. J., Pletnikova, O., Rudow, G., Iacono, D., Riudavets, M. A., Driscoll, I., et al. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1179 · Cited by 137
Resistance to Alzheimer's pathology is associated with nuclear hypertrophy in neurons
Riudavets, M. A., Iacono, D., Resnick, S. M., O’Brien, R., Zonderman, A. B., Martin, L. J., Rudow, G., Pletnikova, O., & Troncoso, J. C. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.05.005 · Cited by 106 · cited 1×
“jects [48–51], suggesting that the endoreduplication”
Cdk5 suppresses the neuronal cell cycle by disrupting the E2F1-DP1 complex
Zhang, J., Li, H., Yabut, O., Fitzpatrick, H., D'Arcangelo, G., & Herrup, K. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5628-09.2010 · Cited by 96 · cited 1×
“plasm [131–135], the loss of nuclear Cdk5 leads to a”
Aβ1–42 stimulates adult SVZ neurogenesis through the p75 neurotrophin receptor
Sotthibundhu, A., Li, Q.-X., Thangnipon, W., & Coulson, E. J. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.02.004 · Cited by 81 · cited 1×
“In differentiated neurons, A 1–42 promotes neurogenesis of subventricular zone precursor cells derived from developing or young adult animals [26, 87–92].”
BackgroundCdk5 and the non-catalytic arrest of the neuronal cell cycle
Zhang, J., & Herrup, K. (2008) · Cell Cycle · doi:10.4161/cc.7.22.7045 · Cited by 44
Hoerndli, F. J., Pelech, S., Papassotiropoulos, A., & Götz, J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05618.x · Cited by 34 · cited 1×
“While both A and P301L tau expression independently affect the regulation of cell proliferation and synaptic elements, cell cycle re-entry as assessed by DNA synthesis is only observed when SH-SY5Y cells overexpressing human wild-type or P301L tau were incubated with A [141].”
MethodLopes, J. P., Blurton-Jones, M., Yamasaki, T. R., Agostinho, P., & LaFerla, F. M. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0993 · Cited by 32 · cited 1×
“[146], although the hormonal status of these young”
BackgroundBialopiotrowicz, E., Kuzniewska, B., Kachamakova-Trojanowska, N., Barcikowska, M., Kuznicki, J., & Wojda, U. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.017 · Cited by 32
Cited by
Therapeutic B-cell depletion reverses progression of Alzheimer’s disease
Kim, K., Wang, X., Ragonnaud, E., Bodogai, M., Illouz, T., DeLuca, M., McDevitt, R. A., Gusev, F., Okun, E., Rogaev, E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22479-4 · Cited by 206
Ercan-Herbst, E., Ehrig, J., Schöndorf, D. C., Behrendt, A., Klaus, B., Gomez Ramos, B., Prat Oriol, N., Weber, C., & Ehrnhoefer, D. E. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0823-2 · Cited by 101
Myelin in Alzheimer’s disease: culprit or bystander?
Maitre, M., Jeltsch-David, H., Okechukwu, N. G., Klein, C., Patte-Mensah, C., & Mensah-Nyagan, A.-G. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01554-5 · Cited by 66
Metadata
- Authors
- Atwood, C. S., & Bowen, R. L.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2015-07-09
- Volume
- 47
- Issue
- 1
- Pages
- 33-47
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2194915957
- Cited by
- 50
- References
- 23
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.